Development and pre-clinical efficacy of an adjuvanted recombinant subunit COVID-19 vaccine

Vaccination is a crucial component of an effective public health strategy against the ongoing COVID-19 pandemic. FDA-approved and Emergency Use Authorized (EUA) vaccines using new mRNA and viral-vector technology are highly effective in preventing moderate to severe disease, however information on their long-term efficacy and protective breadth against SARS-CoV-2 Variants of Concern (VOC) is currently scarce. This seminar will cover the development and pre-clinical evaluation of an adjuvanted, recombinant subunit vaccine in mice and cynomolgus macaques. We show that this vaccine is highly immunogenic and induces robust spike-specific and cross-variant neutralizing antibodies against circulating VOC for at least 3 months after the final boost. Protective efficacy and post-exposure immunity are evaluated using a late, heterologous P.1 (Gamma) challenge model. Our results indicate that our vaccine candidate effectively reduces viral load in the upper & lower respiratory tract and seems protective against disease in macaques even as vaccine immunity wanes.

Albert To, Ph.D.
Postdoctoral Fellow
Department of Tropical Medicine, Medical Microbiology and Pharmacology
John A. Burns School of Medicine, University of Hawaii at Manoa

Wednesday, September 22, 2021
12:00 – 1:00 PM HST

Zoom Details
Link: https://zoom.us/j/97962975142?pwd=aFdJZmhrbjdDOGQ2UFZHITYyeDhUZz09
Meeting ID: 979 6297 5142
Passcode: 306033

For further information, contact Dr. Vivek R. Nerurkar - Tel. 808-692-1668; email: nerurkar@hawaii.edu
Seminar Schedule @ http://manoa.hawaii.edu/tropicalmedicine